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Patients and methods: This study was conducted on 150 patients who were classified into three
groups: Group I: 67 patients with COPD, Group II: 33 COPD patients with co morbidities (dia-
betes mellitus, hypertension and or ischemic heart disease). Group III: (control group): 50 patients
with other diseases such as diabetes mellitus, ischemic heart disease and or hypertension. All
patients were subjected to: (1) Full history taking. (2) Complete clinical examination. (3) Anthro-
pometric measurements (weight, height and body mass index). (4) Arterial oxygen saturation. (5)
Radiological examination (Plain chest X-ray posterior–anterior view and Pelvi-abdominal ultra-
sound). (6) ECG and Echocardiography. (7) Spirometry. (8) Laboratory investigations (complete
blood picture, erythrocyte sedimentation rate, Liver function tests, serum creatinine, blood urea
and uric acid and GFR, total cholesterol, sodium, potassium and chloride concentration).
Results: In group I, there were 8 patients who had CRF (11.94%), 5 patients had overt CRF
(7.46%) and 3 patients had concealed CRF (4.48%). In group II, there were 11 patients with
CRF (33.33%), 6 patients had overt CRF (18.18%) and 5 patients had concealed CRF
(15.15%). In group III, there were 9 patients having CRF (18%), 6 patients had overt CRF
(12%) and 3patients had concealed CRF (6%). In COPD (group I and II) the overall prevalence
of CRF was 19%.
Conclusion: CRF either concealed or overt may be associated with COPD patients and should
be screened, not only by serum creatinine level but also by the estimated GFR to recognize the cases
of concealed CRF who have low GFR despite normal serum creatinine level.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Tuberc.
2 A.H. Al-Aarag et al.Introduction
COPD is associated with several comorbidities. But it is
unknown to which extent it is associated with chronic renal
failure [1]. Coronary artery disease, which is highly prevalent
in patients with COPD, is associated with vascular kidney dis-
ease [2]. Furthermore, both nicotine and selected heavy metals,
which are components of smoke, are risk factors for kidney
disease. Thus, COPD is expected to be significantly associated
with chronic renal failure [3]. Chronic renal failure rises in
prevalence with age, and is frequently associated with chronic
diseases, such as congestive heart failure and diabetes mellitus.
When chronic renal failure presents as comorbidity, it carries
negative prognostic implication and impacts the therapeutic
strategy [4]. In elderly patients, who are the majority of those
suffering from chronic disabling conditions, chronic renal fail-
ure is often associated with normal serum creatinine concen-
tration, a condition known as unrecognized or concealed
chronic renal failure [5]. In fact, a variable, yet consistent, pro-
portion of patients with COPD have a reduced muscular mass
and thus, serum creatinine might be falsely low as the result of
decreased creatine release [6]
Aim of the work
The aim of this work was to assess the prevalence of concealed
and overt chronic renal failure in patients with COPD.Subjects and methods
This case control cross sectional study was conducted on 150
patients who were attendant in Benha University Hospitals
chest and internal medicine outpatient clinics during the period
from October 2013 to April 2015. They were classified into
three groups: Group I: 67 patients with COPD. Group II: 33
COPD patients with co morbidities such as diabetes mellitus,
hypertension and or ischemic heart disease. All COPD patients
were diagnosed according to criteria of GOLD [7]. Group III:
(control group): 50 patients with other chronic diseases as dia-
betes mellitus, ischemic heart disease and or hypertension, all
of them were lifelong nonsmokers; they had no symptoms or
signs suggestive of any chest diseases.
Exclusion criteria: Patients with diagnosis of cancer,
regardless of disease activity, abnormal chest radiography
other than that of COPD, Known immune deficiency state
as aplastic anemia, leukemia and multiple myeloma, use of
drugs which may affect serum creatinine levels or renal func-
tion test as ACEI, cyclosporine and chemotherapy drugs (cis-
platin, carboplatin, methotrexate and mitomycin), patients
with acute or chronic renal failure and on dialysis.
All patients were subjected to the following: (1) Full history
taking including history of smoking (2) Complete clinical
examination with special attention to manifestations of hyper-
inflation in the COPD group (increase the antero-posterior
diameter, use of accessory muscles of respiration and distant
heart sounds). (3) Anthropometric measurements (weight
(kg), Height (m), BMI =Wt (kgnHt (m2) (4) Arterial oxygen
saturation. (5) Radiological examination (Plain chest X-ray
posterior-anterior view and Pelvi-abdominal ultrasound). (6)
ECG and Echocardiography. (7) Spirometry: by using anPlease cite this article in press as: A.H. Al-Aarag et al., Prevalence of concealed and
(2016), http://dx.doi.org/10.1016/j.ejcdt.2016.09.002automated flow-sensing spirometer (spirolab ΙΙΙ Ver 4.3 SN
311860 (Italy)) all COPD patients included in the study per-
formed prebronchodilator and postbronchodilator spirometry
according to American Thoracic Society (ATS) criteria [8].
Separate measurements were made before and at least 15 min
after two puffs of Salbutamol (200 mg) administered with a
metered dose inhaler. Irreversible airway obstruction was
defined as a postbronchodilator FEV1/FVC < 0.7 and post-
bronchodilator change in FEV1 < 12% and FEV1 was used
to further stage the disease: mild (GOLD stage I, FEV1 pre-
dictedP 80%), moderate (GOLD stage II, 50% 6 FEV1 pre-
dicted < 80%), severe (GOLD stage III, 30% 6 FEV1
predicted < 50%) and very severe (GOLD stage IV, FEV1
predicted < 30% or 30% 6 FEV1 predicted < 50% in the
presence of corpulmonale or respiratory failure) [7]. (8) Labo-
ratory investigations: Blood samples were taken for the follow-
ing investigations:-Complete blood picture -Erythrocyte
sedimentation rate (ESR). -Liver function tests: SGPT, SGOT,
serum total protein and albumin concentrations. -Kidney
function tests: serum creatinine, blood urea -Total cholesterol.
-Sodium, potassium and chloride concentration.
9- The GFR was estimated using the Modification of Diet
in Renal Disease (MDRD) Study Group equation:
170 ½serum creatinine0:999  ½age0:176  ½blood urea0:170
 ½serum albumin0:318  ð0:762 for womenÞ
 ð1:180 for African-American subjectsÞ: ½9
Patients were categorized according to their renal function
as having normal renal function (GFRP 60 mL/
min/1.73 m2), concealed CRF (normal serum creatinine and
GFR< 60 mL/min/1.73 m2), or overt CRF (increased serum
creatinine and GFR< 60 mL/min/1.73 m2). The cutoff used
for serum creatinine was 1.26 mg/dL in men and 1.04 mg/dL
in women [9].
Statistical analysis
The clinical datawere recordedona report form.These datawere
tabulated and analyzed using the computer program SPSS (Sta-
tistical package for social science) version 16 to obtain: (1)
Descriptive statistics were calculated for the data in the form
of:- Mean and standard deviation for quantitative data, Fre-
quency anddistribution for qualitative data. (2)Analytical statis-
tics: In the statistical comparison between the different groups,
the significanceof differencewas testedusing oneof the following
tests:- Student’s t-test and Mann–Whitney test:- Used to com-
pare mean of two groups of quantitative data of parametric
and non-parametric respectively. Inter-group comparison of cat-
egorical data was performed by using chi square test (X2-value)
and fisher exact test (FET).Degree of significance: p value<0.05
was considered statistically significant (S), p value >0.05 was
considered statistically insignificant, p value <0.01 was consid-
ered highly significant (HS) in all analyses.Results: (Tables 1–8)
Distribution of the studied groups was shown in Table 1.
Group I included 67 patients, 53males (79.1%) and 14
females (20.9%), group II included 33 patients, 22 malesovert chronic renal failure in patients with COPD, Egypt. J. Chest Dis. Tuberc.
Table 1 Distribution of the studied groups.
Group Associated disease
None DM HTN IHD Combined Total
Group I (COPD only) 67 (100%) 0 (0.0%) 0 (.0%) 0 (0.0%) 0 (0.0%) 67 (100%)
Group II (COPD with comorbidities) 0 (0.0%) 21 (63.64%) 5 (15.15%) 0 (0.0%) 7 (21.21%) 33 (100%)
Group III (control) 0 (0.0%) 8 (16%) 0 (0.0%) 4 (8%) 38 (76%) 50 (100%)
Total 67 (44.67%) 29 (19.33%) 5 (3.33%) 4 (2.67%) 45 (30%) 150 (100%)
Table 2 Comparison between the studied groups regarding the demographic data.
Variable Group I Group II Group III T test
P1 P2 P3
Sex
Male
Female
53 (79.1%)
14 (20.9%)
22 (66.7%)
11 (33.3%)
36 (72.0%)
14 (28.0%)
0.177 0.0373 0.604
Age (years)
Mean ± SD
(Range)
56.13 ± 9.77
(44–68)
54.85 ± 10.49
(44–62)
58.92 ± 8.47
(45–67)
0.547 0.109 0.055
BMI
Mean ± SD
(Range)
22.19 ± 2.81
(17.75–33.33)
22.61 ± 3.45
(17.8–34.0)
22.43 ± 4.11
(16.0–38.0)
0.52 0.711 0.837
Duration of disease(years)
Mean ± SD
(Range)
9.1 ± 6.77
(2–30)
15.48 ± 9.91
(2–40)
– 0.001 – –
Smoking index
Mean ± SD
(Range)
505.97 ± 166.97
(150–1000)
591.56 ± 222.64
(200–1000)
– 0.039 0.001 0.001
P1 between group I and group II, P2 between group I and group III, P3 between group II and group III.
Prevalence of concealed and overt chronic renal failure in patients with COPD 3(66.7%) and 11 females (33.3%), group III included 50
patients, 36 males (72%) and 14 females (28%) (Table 2). In
group I the age ranged from 44 to 68 years with a mean age
of 56.13 ± 9.77, in group II it ranged from 44 to 62 years with
a mean age of 54.85 ± 10.49, in group III it ranged from 45 to
67 years with a mean age of 58.92 ± 8.47 (Table 2). Regarding
the laboratory data, there was a statistically significant differ-
ence between group I and II regarding Sao2 as it was lower in
group II (94.52 ± 1.72) compared to group I (95.69 ± 2.0 and
group III (95.48 ± 0.95) (Table 3).
Regarding hemoglobin concentration, there was a high sta-
tistically significant difference between group I and III and
between group II and III as it was lower in group III (Table 3).
There was a statistically significant difference between group II
and III as regards serum urea level as it was higher in group II
(Table 3).
Comparing CRP level in the three groups, it was higher in
group II than group I and the difference was statistically signif-
icant (p< 0.05). CRP was also very high in group I and II
compared to group III (15.55 ± 4.22, 17.45 ± 5.07, 4.94
± 3.61 respectively) and the difference was statistically highly
significant (p< 0.001) (Table 3). There was a statistically sig-
nificant difference between group I and II as regards GFR as it
was lower in group II (p< 0.05) (Table 3). Regarding the pul-
monary function, there is no statistically significant difference
between group I and II as regards pulmonary function param-
eters (Table 4). Regarding COPD severity most of cases had
severe disease (56.71% in group I and 54.54% in group II)Please cite this article in press as: A.H. Al-Aarag et al., Prevalence of concealed and
(2016), http://dx.doi.org/10.1016/j.ejcdt.2016.09.002(Table 5). The overall prevalence of CRF was 18.7%
(28/150). In COPD (group I and II), it was 19% (19/100), while
in the control group (group III), it was 18% (9/50) (Table 6).
In group I: 8 patients had CRF (11.94%), 5 patients of them
had overt CRF (7.46%) and 3 patients had concealed CRF
(4.48%). In group II: 11 patients had CRF (33.33%), 6patients
of them had overt CRF (18.18%) and 5patients had concealed
CRF (15.15). In group III: 9 patients had CRF (18%), 6
patients had overt CRF (12%) and 3patients had concealed
CRF (6%) (Table 7).
There was a statistically significant difference between cases
with and without renal failure regarding hemoglobin concen-
trations it was lower in cases with renal failure (Table 8). There
was also a statistically significant difference between cases with
and without renal failure regarding Sao2 as it was lower in
cases with renal failure; there were also an increase in age,
urea, total cholesterol and potassium in cases with renal failure
(Table 8).
There was a statistically significant increase in the incidence
of renal failure in cases with severe and very severe COPD than
cases with moderate severity; there was also significant increase
in smoking index in cases with renal failure (Table 8).
Discussion
Chronic renal failure (CRF) rises in prevalence with age and is
frequently associated with chronic diseases such as congestive
heart failure and diabetes mellitus. When present as co mor-overt chronic renal failure in patients with COPD, Egypt. J. Chest Dis. Tuberc.
Table 3 Comparison between the studied groups regarding the laboratory data.
Variable Group I Group II Group III T test
P1 P2 P3
Hb concentration(gm/dl)
Mean ± SD
(Range)
12.64 ± 1.31
10–15.1
12.83 ± 1.25
11–15.1
11.1 ± 1.24
9–14
0.50 0.001 0.001
SAo2
Mean ± SD
(Range)
95.69 ± 2.0
(90–98)
94.52 ± 1.72
(92–98)
95.48 ± 0.95
(94–97)
0.005 0.501 0.001
ESR(mm/h)
Mean ± SD
(Range)
35.15 ± 30.29
(5–155)
44.55 ± 29.85
(5–130)
34.88 ± 21.73
(5–125)
0.146 0.957 0.092
Total protein(gm/dl)
Mean ± SD
(Range)
7.07 ± 0.27
(6.7–8)
6.97 ± 0.37
(6–8)
7.04 ± 0.26
(6.5–8)
0.134 0.596 0.298
S. albumin(gm/dl)
Mean ± SD
(Range)
3.46 ± 0.47
(2.3–5.0)
3.58 ± 0.42
(2.7–4.5)
3.60 ± 0.54
(2.8–5.0)
0.195 0.14 0.906
Creatinine(mg/dl)
Mean ± SD
(Range)
1.11 ± 0.36
(0.6–2.6)
1.24 ± 0.40
(0.6–2.2)
1.11 ± 0.41
(0.6–2.4)
0.112 0.96 0.177
Urea(mg/dl)
Mean ± SD
(Range)
43.57 ± 30.35
(15–199)
52.3 ± 31.79
(20–167)
40.48 ± 20.89
(20–100)
0.186 0.538 0.044
Total cholesterol(mg/dl)
Mean ± SD
(Range)
129.9 ± 17.91
(90–188)
149.94 ± 28.16
(111–230)
124.8 ± 14.74
(100–190)
0.001 0.104 0.001
CRP(mg/L)
Mean ± SD
(Range)
15.55 ± 4.22
(5–32)
17.45 ± 5.07
(12–30)
4.94 ± 3.61
(1–18)
0.05 0.001 0.001
Sodium(mEq/L)
Mean ± SD
(Range)
137.24 ± 5.43
(121–148)
138.46 ± 6.77
(126–160)
135.46 ± 3.93
(124–149)
0.335 0.051 0.012
Potassium(mEq/L)
Mean ± SD
(Range)
4.03 ± 0.71
(3.0–5.5)
4.31 ± 0.58
(3.1–5.6)
4.1 ± 0.59
(3.0–5.0)
0.05 0.563 0.112
Chloride(mEq/L)
Mean ± SD
(Range)
99.36 ± 2.61
(94–105)
99.55 ± 2.2
(95–103)
99.78 ± 2.87
(95–105)
0.724 0.409 0.691
GFR
Mean ± SD
(Range)
88.64 ± 24.98
(25.8–130.8)
76.48 ± 27.77
(32.7–130.8)
84.85 ± 25.87
(30.5–129)
0.03 0.426 0.165
P1 between group I and group II, P2 between group I and group III, P3 between group II and group III.
4 A.H. Al-Aarag et al.bidity, CRF carries negative prognostic implications and
impacts the therapeutic strategy [10]. It is unknown to which
extent COPD is associated with CRF and the relationship
between renal failure and COPD is largely undescribed. A pro-
portion of patients with COPD have a reduced muscular mass,
and thus, serum creatinine might be falsely low as the result of
decreased creatine release [11]. In the present study, there was
no statistically significant difference between the 3 studied
groups regarding BMI (Table 2). This result wasn’t in accor-
dance with Elmahallawy and Qora, who studied the prevalence
of CRF in COPD patients, their study included 300 COPD
patients and 300 controls with other diseases, in their studyPlease cite this article in press as: A.H. Al-Aarag et al., Prevalence of concealed and
(2016), http://dx.doi.org/10.1016/j.ejcdt.2016.09.002BMI was significantly increased in the control than in COPD
group [12], as weight loss can be frequently found in COPD
patients and is considered to be part of the commonly preva-
lent non pulmonary sequel of the disease [13]. The difference
in results between the present and the former study can be
explained by the different distribution of the control groups.
Regarding duration of disease, there was a statistically signifi-
cant difference between group I and II as it was longer in
group II. This result was in accordance with Elsawy, who stud-
ied the prevalence of chronic renal failure in COPD patients;
her study measured the GFR for 527 subjects (327 COPD
patients and 200 diabetic patients) using the Modification ofovert chronic renal failure in patients with COPD, Egypt. J. Chest Dis. Tuberc.
Table 4 Comparison between group I and II regarding pulmonary functions.
Pulmonary functions Group I Group II St t test p value
FEV1% (mean ± SD) 36.07 ± 7.47 37.27 ± 7.8 0.743 0.459
Range (18–51) (17–55)
FEV1/FVC% (mean ± SD) 63.87 ± 6.27 63.15 ± 11.27 0.407 0.685
Range (44–60) (45–65)
Post bronchodilator FEV1 change%(mean ± SD) 3.73 ± 2.95 3.82 ± 3.15 0.135 0.893
Range 0–11% 0–9%
Table 5 Comparison between group I and II regarding COPD severity.
Degree of severity Group I Group II FET p value
Moderate
Severe
Very severe
11 (16.41)%
3 8 (56.71)%
18 (26.9)%
9 (27.8)%
18 (54.54)%
6 (18.2)%
1.39 0.514
Table 6 Distribution of the studied groups regarding the
presence of renal failure.
RF Group
Group I and II Group III Total
Present 19 (19%) 9 (18%) 28 (18.7%)
Absent 81 (81%) 41 (82%) 22 (81.3%)
Total 100 (100%) 50 (100%) 150 (100%)
Prevalence of concealed and overt chronic renal failure in patients with COPD 5Diet in Renal Diseases (MDRD) study group equation; in her
study, disease duration was significantly increased in COPD
with either HTN or DM than those with COPD only (p
0.000) [14]. As regards smoking index, there was a statistically
significant difference between group I and II as it was higher in
group II and between group I and III as it was higher in group
I and between group II and III as it was higher in group II, this
result was also in agreement with Elsawy as smoking index was
significantly increased in COPD with either HTN or DM than
those with COPD only (p 0.000) [14]. This may explain the
relation between smoking and other co morbidities such as
hypertension, DM and coronary heart diseases as follows:
(1) The immediate noxious effects of smoking are related to
sympathetic nervous overactivity which increases myocardial
O2 consumption through a rise in blood pressure, heart rate
and myocardial contractility [15]. (2) The incidence of hyper-
tension is increased among those who smoke 15 or more cigar-
ettes per day [16]. (3) Several studies in Korea have reported
that smoking was associated with an increased risk for the
development of DM [17]. In addition, smoking causes increaseTable 7 Comparison between the studied groups regarding the pre
Group Renal failure
Overt Concealed
Group I 5 (7.46%) 3 (4.48%)
Group II 6 (18.18%) 5 (15.15%)
Group III 6 (12%) 3 (6%)
Total 17 (60.71%) 11 (39.29%)
Please cite this article in press as: A.H. Al-Aarag et al., Prevalence of concealed and
(2016), http://dx.doi.org/10.1016/j.ejcdt.2016.09.002insulin resistance [18]. (4) Smoking is a well-known risk factor
for coronary heart diseases [19]. It is caused probably by vas-
cular disability via its pathological changes such as arterioscle-
rosis through the mechanisms of inflammation and endothelial
dysfunction [20]. In the present study, there was a statistically
significant difference between group II and III as regards
serum urea level as it was higher in group II. This result was
also in agreement with Elsawy, in her study blood urea in
group II (COPD with comorbidities) was 42.56 ± 26.71 while
in group I (COPD alone) it was 36.48 ± 12.64 [14]. This may
be attributed to associated diseases such as DM as plasma urea
concentration increases in diabetic patients [21]. Regarding
serum cholesterol, it was higher in group II than group I and
group III and the difference was statistically highly significant
(p< 0.001). This increase in serum cholesterol in group II
(COPD with comorbidities) may be due to other associated
diseases such as hypertension and DM in which there is
increase in total cholesterol. It was explained by the following:
(1) The epidemiological investigations have found that hyper-
tensive patients frequently have a concomitant increase in
serum cholesterol level [22]. Moreover, there is evidence that
cholesterol induces endothelial dysfunction in experimental
and clinical studies by reducing the bioavailability of
endothelium-derived nitric oxide [23]. (2) Smokers have higher
fasting triglycerides and lower high density lipoprotein and
high proportion of low density lipoprotein particles [24]. (3)
According to the American Diabetes Association, people with
DM have higher rates of cholesterol abnormalities than the
rest of population and this contributes to the higher rates of
heart diseases in people with DM [25]. Comparing CRP level
in the three groups, it was higher in group II than group Isence of renal failure (overt and concealed).
Total FET p value
8 (11.94%) 0.43 0.892
11 (33.33%)
9 (18%)
28 (100%)
overt chronic renal failure in patients with COPD, Egypt. J. Chest Dis. Tuberc.
Table 8 Comparison between COPD patients with and without renal failure regarding (age, Hb concentration, Sao2, total
cholesterol, urea, potassium, sodium, GFR, duration of disease, smoking index, BMI, CRP and severity of the disease).
Variable RF
Present (19) Absent (81) St t test p value
Age(years)
Mean ± SD 71.26 ± 7.59 57.91 ± 8.37 6.36 0.001
Hb concentration(gm/dl)
Mean ± SD 11.7 ± 61.1 12.1 ± 7.3 X2 = 4.24 0.04
Sao2
Mean ± SD 94.21 ± 2.2 95.56 ± 1.8 2.75 0.007
Urea(mg/dl)
Mean ± SD 88.58 ± 45.02 36.57 ± 14.44 8.76 0.001
Total cholesterol(mg/dl)
Mean ± SD 156.05 ± 32.8 131.93 ± 18.37 4.35 0.001
Potassium(mEq/L)
Mean ± SD 4.59 ± 0.68 4.01 ± 0.63 3.54 0.001
GFR
Mean ± SD 44.41 ± 8.5 94.06 ± 19.33 10.92 0.001
severity Moderate
Severe
Very severe
1 (5.3%)
9 (47.4%)
9 (47.4%)
1 (1.2%)
65 (80.2%)
15 (18.5%)
FET= 8.75 0.011
Duration of disease(years)
Mean ± SD 15.06 ± 10.93 10.57 ± 8.05 1.83 0.072
Smoking index
Mean ± SD 605.88 ± 235.77 480.43 ± 164.82 2.38 0.021
BMI
Mean ± SD 22.2 ± 4.03 21.95 ± 2.65 0.295 0.769
CRP(mg/L)
Mean ± SD 16.22 ± 3.52 17.2 ± 5.16 0.745 0.459
Sodium(mEq/L)
Mean ± SD 138.4 ± 8.81 138.25 ± 5.05 0.085 0.933
6 A.H. Al-Aarag et al.and the difference was statistically significant (p< 0.05). CRP
was also very high in group I and II compared to group III and
the difference was statistically highly significant (p< 0.001).
Chronic inflammation in COPD is orchestrated by multiple
inflammatory cells and mediators in the airways and the lung
tissues induced by inhalation of noxious gases and particular
matter, this persistent inflammatory response in the lungs is
also associated with a significant systemic inflammatory
response yielding adverse clinical outcomes, so called systemic
effects of COPD [26]. It is clearly established that some inflam-
matory markers rise in systemic circulation [27], of the blood-
based biomarkers, CRP has shown the greatest promise [28].
Smoking, as well as COPD itself, the most commonly encoun-
tered risk factor for the disease is also responsible for rise in
serum CRP levels [29]. In the current study, there was a statis-
tically significant difference between group I and II as regards
GFR as it was lower in group II (p< 0.05). This is in agree-
ment with Elsawy, who reported that the mean ± SD of calcu-
lated GFR by MDRD in COPD was 82.63 ± 23.30 ml/
min/1.73 m2, while in COPD with either HTN or DM was
80.99 ± 26.64 ml/min/1.73 m2 [14].These results may be due
to associated diseases as several lines of evidence have shown
that smoking increases the risk and progression of diabetic
nephropathy [30]. Analysis of a number of risk factors showedPlease cite this article in press as: A.H. Al-Aarag et al., Prevalence of concealed and
(2016), http://dx.doi.org/10.1016/j.ejcdt.2016.09.002a 1.6-fold increases risk of nephropathy among smokers [31].
DM is the most common cause of renal failure, accounting
for nearly 44% of new cases. The cause of diabetic nephropa-
thy is not well understood, but it is thought that increased
blood sugar, advanced glycation end product formation and
cytokines may be involved in the development of diabetic
nephropathy. DM causes changes in the body metabolism
and blood circulation, which likely combine to produce excess
reactive O2 species. These changes damage the glomeruli of the
kidneys which lead to albuminuria [32]. The prevalence of
reduced GFR is also high in older hypertensive patients [33].
Elmahallawy and Qora reported that the mean estimated
GFR in their COPD group was 75.20 ± 35.78 ml/
min/1.73 m2,while for the control group it was 92.04
± 25.54 ml/min/1.73 m2 with highly significant decrease in
GFR in COPD group (p< 0.01) [12]. The lower GFR in
COPD group in their study may be attributed to that their
patient were older with more severe airflow limitation and
68% of them had chronic respiratory failure.
In our study, the overall prevalence of CRF was 18.7%
(28/150). In COPD (group I and II), it was 19% (19/100), while
in the control group (group III), it was 18% (9/50). In group I,
8 patients had CRF (11.94%), 5 patients of them had overt
CRF (7.46%) and 3 patients had concealed CRF (4.48%). Inovert chronic renal failure in patients with COPD, Egypt. J. Chest Dis. Tuberc.
Prevalence of concealed and overt chronic renal failure in patients with COPD 7group II, 11 patients had CRF (33.33%), 6patients of them
had overt CRF (18.18%) and 5patients had concealed CRF
(15.15). In group III, 9 patients had CRF (18%), 6 patients
had overt CRF (12%) and 3patients had concealed CRF
(6%). In a study by Elsawy, concealed CRF in COPD group
was 17.55% (46n262) while 1.52% (4n262) had overt CRF,
in COPD with comorbidities, 18.46% (12n65) had concealed
CRF while 6.15% (4n65) had overt CRF, and in the control
group 10% (20n200) had concealed CRF while 2% (4n200)
had overt CRF. The main finding of her study was the high
prevalence of chronic renal failure (concealed and overt)
among patients with COPD [14]. In Elmahallawy and Qora
study, the overall prevalence of CRF was 46% in the study
group and 22% in the control group. In their study, in COPD
group, concealed CRF was 26% and overt CRF was 20%
while in the control group, 10% of patients had concealed
CRF and 12% of patients had overt CRF [12], the higher fre-
quency of CRF in this study may be explained by: - First: 68%
of their patients had chronic type 2 respiratory failure. Second:
72% of their patients had very severe COPD. Raffaele et al.
found that the overall prevalence of CRF was 43.0% in the
COPD group and 23.4% in the control group (DM hypoalbu-
minemia and skeletal muscle diseases) [7]. According to
National kidney foundation, [34], if serum creatinine greater
than 1.26 mgndl for men and 1.04 mgndl for women, it is con-
sidered a reliable marker of CRF. The GFR is frequently
decreased in patients with COPD despite normal serum crea-
tinine, so in our study (28.6%) of COPD patients have low
GFR despite normal serum creatinine (concealed CRF) in
comparison to (10.7%) in the control group. In a large multi-
national survey addressing the impact of COPD in North
America and Europe in 2000, done by Rennand et al.
(11.3%) of participating COPD patients were found to have
CRF [35]. Gestel et al. studied the association between COPD
and CKD in 3358 patients who underwent elective vascular
surgery between January 1990 and December 2006 in the
Netherlands, they found that COPD was associated with a
higher risk of prevalent CKD as COPD patients were 2.19
times more likely to have concealed CRF and 1.94 times more
likely to have overt CRF than controls [36]. Lower figures were
found by Gjerde et al. who studied the prevalence of undiag-
nosed renal failure in COPD patients in Western Norway, they
found that the prevalence of patients having CRF
(GFR< 60 mlnminn1.73m2) was 9.6% in female COPD
patients and 5.1% in male COPD patients [37]. Chandra
et al. also found a significant association between radio graph-
ically measured emphysema in COPD patients and GFR, par-
ticipants with 10% more emphysema had GFR which was
lower by 4, 4 mlnminn1.73m2 (p= 0.01) [38]. The association
between COPD and CRF may be explained by several factors.
First; it was found that arteriolar renal resistance is increased
in COPD patients, perhaps because of local adrenergic dis-
charge secondary to hypercapnia, in the initial phase of
COPD, renal perfusion is usually normal but as the disease
worsens, particularly as CO2 retention develops, renal blood
flow decrease. PaCO2 has been found to correlate inversely
with ERPF (effective renal plasma flow) and with the ability
to excrete sodium and water. Hypercapnia may cause renal
vasoconstriction directly and indirectly by stimulating sympa-
thetic tone as detected by the increase in the circulating levels
of norepinephrine [39]. Second; both nicotine and selected
heavy metals as lead and cadmium, which are components ofPlease cite this article in press as: A.H. Al-Aarag et al., Prevalence of concealed and
(2016), http://dx.doi.org/10.1016/j.ejcdt.2016.09.002smoke, are risk factors for CRF. Nicotine causes nephropa-
thies with an increased incidence of microalbuminurea pro-
gressing to proteinuria [40]. Third; COPD is generally
recognized as a cause of systemic inflammation. Pro-
inflammatory cytokines, especially (TNFa), play an important
role in the disease process. In addition to pulmonary inflam-
mation, several other parts of the body are affected resulting
in muscle wasting, weight loss, diabetes, osteoporosis,
atherosclerosis and renal dysfunction. So, the systemic inflam-
mation seen in patients with COPD might explain the associa-
tion between COPD and CRF [41]. Fourth, Pulmonary
hypertension secondary to COPD, may be associated with
the progression of kidney diseases [37]. Fifth, coronary artery
disease, which is highly prevalent in COPD patients, is associ-
ated with vascular kidney disease [42]. This high prevalence of
CRF found in COPD patients might explain the association
between COPD and a large number of other comorbidities:-
First; renal impairment is expected to be associated with
decreased activity of renal a1 –hydroxylase with subsequent
lower levels of the mean serum 25-hydroxy vitamin D than
those with normal renal function. This may be an important
factor underlying the association between COPD and osteo-
porosis [43]. Second, the prevalence of anemia in COPD
patients is thought to be secondary to chronic inflammation
and to a lesser extent to iron and folate deficiencies [39]. Third,
CRF is associated with increased serum levels of inflammatory
biomarkers and pro-thrombotic molecules. Thus, CRF may
add to the factors explaining the association between COPD
and cardiovascular diseases [44]. Finally, most drugs com-
monly used in the treatment of COPD exacerbations and
comorbidities and as a result, the association between COPD
and CRF will make COPD patients at high risk for adverse
drug reactions to water soluble drugs so drug prescribing
and dosing should be adjusted [45]. In the current study, there
was a statistically significant difference between COPD
patients with and without renal failure regarding hemoglobin
concentrations as it was lower in cases with renal failure and
this can be explained as CRF may be an important underlying
cause of anemia through impaired production of erythropoi-
etin [46]. In this study, there was a statistically significant dif-
ference between COPD patients with and without renal failure
regarding Sao2 as it was lower in cases with renal failure. The
relation between hypoxia and renal failure may be due to the
effect of hypoxia which induces collagen messenger RNA
expression and induces tissue inhibitors of metalloproteinases.
Hypoxia also promotes the trans-differentiation of proximal
tubular cells into myofibroblasts [47]. In our study, there was
a statistically significant increase in the incidence of renal fail-
ure in COPD patients with severe and very severe COPD than
cases with moderate severity. This may be explained by the fact
that patients with severe COPD in the stable state may have a
reduced or absent renal functional reserve [48]. Raffaele et al.
reported that GFR values were not significantly associated
with COPD severity, the investigators noted (older age and
select co morbidities more than COPD severity-are associated
with renal dysfunction in COPD) [3]. Corsonello et al. stated
that the correlation between renal function and COPD severity
warrants further investigations [45]. In the current study, there
was significant increase in smoking index in COPD patients
with renal failure as both nicotine and selected heavy metals
as lead and cadmium, which are components of smoke, are risk
factors for CRF. Nicotine causes nephropathies with anovert chronic renal failure in patients with COPD, Egypt. J. Chest Dis. Tuberc.
8 A.H. Al-Aarag et al.increased incidence of microalbuminurea progressing to pro-
teinuria [40]. Lead and cadmium cause nephrotoxicity in the
form of tubular proteinuria and glomerular dysfunction evi-
denced by an increased excretion of high molecular weight pro-
teins and increased levels of creatinine in plasma and giving
rise to a glomerular type proteinuria [49].
Conclusion
Chronic renal failure may be associated with COPD and
should be screened for not only by serum creatinine level but
also by the estimated GFR to recognize the cases of concealed
CRF who have low GFR despite normal serum creatinine level
because its recognition might either directly affect clinical
practice or has prognostic implications. The increase in age,
urea, total cholesterol, potassium, severity of airway obstruc-
tion, smoking index, low Sao2 and low hemoglobin concentra-
tion in COPD patients may increase the possibility of this
association.
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